Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Femasys Inc. - Common Stock (NQ:FEMY)

0.3689 -0.0211 (-5.41%)
Streaming Delayed Price Updated: 1:48 PM EDT, Sep 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Femasys Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Top stock movements in today's session.
Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Tuesday's session: top gainers and losers
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
The Latest Analyst Ratings For Femasys
 
Via Benzinga
Femasys Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
 
Via Benzinga
Deep Dive Into Femasys Stock: Analyst Perspectives (4 Ratings)
 
Via Benzinga
Crude Oil Down 2%; US Durable Goods Orders Decline In July
 
Via Benzinga
Traders are paying attention to the gapping stocks in Tuesday's session.
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday. 
Via Chartmill
US Stocks Mixed; American Woodmark Posts Downbeat Sales
 
Via Benzinga
Tuesday's pre-market session: top gainers and losers
Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Why Serina Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Femasys Revenue Jumps 85 Percent in Q2
Via The Motley Fool
Topics Intellectual Property
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
The Analyst Verdict: Femasys In The Eyes Of 6 Experts
 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Femasys Stock Slides After Company Prices Public Offering At Discount: Retail’s Planning To Load Up
The offer price of $0.85 represents a discount of about 17% from the stock’s closing price on Thursday. 
Via Stocktwits
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
What's going on in today's after hours session
After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
Analyst Expectations For Femasys's Future
 
Via Benzinga
Femasys Reports Wider-Than-Expected Annual Loss, But Retail Continues To Be Optimistic
The company said that as of the end of 2024, it had an accumulated deficit of $127.2 million and cash and cash equivalents of only $3.5 million. 
Via Stocktwits
Assessing Femasys: Insights From 4 Financial Analysts
 
Via Benzinga
Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
FEMY Stock Earnings: Femasys Misses EPS, Misses Revenue for Q2 2024
FEMY stock results show that Femasys missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Dow Jumps Over 300 Points; Zapp Electric Vehicles Group Shares Spike Higher
 
Via Benzinga
Topics Stocks
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Gold Rises 1%; Accenture Shares Surge After Q3 Results
 
Via Benzinga
EXCLUSIVE: Femasys At Inflection Point And Undervalued, Expects Growth Potential Following Roe v. Wade Overturn, CEO Says
Femasys focuses on innovative women's healthcare solutions. Their FemBloc product, a non-surgical permanent birth control, is in late-stage development, aiming for a $20 billion market. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.